Bovex 2.265% W/V Oral Suspension For Cattle And Sheep
Revised: January 2014
SUMMARY OF PRODUCTS CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Bovex 2.265% w/v Oral Suspension for Cattle and Sheep
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active Substance: mg
Methyl Parahydroxybenzoate 2.0
Propyl Parahydroxybenzoate. 0.2
For a full list of excipients, see section 6.1
White to off-white coloured suspension
Cattle and sheep
4.2 Indications for use, specifying the target species
A broad spectrum worm drench for cattle and sheep indicated for the control of mature and developing immature forms of gastrointestinal roundworms, lungworms and tapeworms. The product is also ovicidal against nematode eggs.
In cattleit is active against the following species:
Roundworms: Ostertagia spp, Haemonchus spp, Trichostrongylus spp, Nematodirus, Cooperia spp, Capillaria spp, Oesophagostomum spp, Chabertia spp, and Trichuris spp;
Lungworms: Dictyocaulus spp;
Tapeworms: Moniezia spp.
It is usually effective in the control of Type II Ostertagiasis.
In sheepit is active against benzimidazole susceptible strains of the following species:
Roundworms: Ostertagia spp, Haemonchus spp, Trichostrongylus spp, Nematodirus, (including N. battus), Cooperia spp, Oesophagostomum spp, and Chabertia spp (also provides useful control of Trichuris).
Lungworms: Dictyocaulus spp;
Tapeworms: Moniezia spp
Not for use in animals known to be hypersensitive to the active ingredient.
4.4 Special warnings for
Care must be taken not to damage the pharyngeal region when dosing, particularly in sheep.
Intensive use or misuse of anthelmintics can give rise to resistance. To reduce this risk, dosing programmes should be discussed with a veterinary surgeon.
Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy
Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g., Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used.
Resistance to benzimidazoles (which include oxfendazole) has been reported in Teladorsagia, Haemonchus, Cooperia and Trichostrongylus species in small ruminants in a number of countries, including the EU. Resistance to albendazole has been reported in Cooperia and Teladorsagia species in cattle in developed countries such as New Zealand. Therefore, the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selsction for resistance to anthelmintics.
4.5 Special precautions for use
Special precautions for use in animals
Assess bodyweight as accurately as possible before calculating the dosage.
Special precautions for the person administering the veterinary medicinal product to animals
Avoid contact with the skin and eyes. Wash any splashes immediately with cold water. Wear suitable protective clothing including impermeable rubber gloves. Wash hands after use.
4.6 Adverse reactions (frequency and seriousness)
4.7 Use during pregnancy, lactation or lay
No known contra-indications for the use of Bovex 2.265% during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
4.9 Amounts to be administered and administration route
Shake the container before use. Avoid the introduction of contamination during use.
For oral administration only using properly calibrated dosing equipment. Estimate bodyweight accurately. Each ml of Bovex 2.265% contains 22.65 mg oxfendazole.
The dosage rates are as follows:
Cattle:4.5 mg oxfendazole per kg bodyweight, equivalent to 5 ml per 25 kg bodyweight.
Sheep: 5 mg oxfendazole per kg bodyweight, equivalent to 1 ml per 4.5 kg bodyweight.
100 kg (2 cwt)
Up to 9 kg (19 lb)
150 kg (3 cwt)
10 to 13.5 kg (22 to 30 lb)
200 kg (4 cwt)
14 to 18 kg (31 to 40 lb)
250 kg (5 cwt)
19 to 22.5 kg (42 to 49.5 lb)
300 kg (6 cwt)
23 to 27 kg (51 to 59 lb)
Cattle above 300 kg should be given a further 5 ml for each additional 25 kg bodyweight.
Sheep above 27 kg should be given a further 1 ml for each additional 4.5 kg bodyweight.
To ensure administration of a correct dose, body weight should be determined as accurately as possible; accuracy of the dosing device should be checked.
Do not mix with other products.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No treatment specified. Benzimidazoles has a wide margin of safety.
4.11 Withdrawal period
Meat: 19 Days
Milk: 84 hours
Meat: 24 Days
Not for use in sheep producing milk for human consumption.
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Anthelmintics: Benzimidazoles and related substances; Oxfendazole
ATCvet code: QP52AC02
5.1 Pharmacodynamic properties
The active ingredient is oxfendazole, one of the benzimidazole group of compounds with anthelmintic activity. Benzimidazoles bind to nematode tubulin, a protein necessary for the formation and viability of microtubules, primarily in the absorptive intestinal cells of the nematode. This results in a complete absence of microtubules in the intestinal cells leading to a reduction in the absorption of nutrients, a reduction in glycogen and the effective starvation of the parasite.
Structural differences between tubulin from mammalian and helminth sources results in the preferential toxicity of oxfendazole to the helminth and not to the host. Benzimidazoles have also been shown to inhibit the fumarate reductase system of helminths and impair energy production.
5.2 Pharmacokinetic properties
Oxfendazole is slowly and incompletely absorbed after oral administration, with Cmax reached between 15 and 30 hours, followed by slow elimination. This slow rate of absorption and elimination means that the drug is in contact with the helminths for significantly long periods of time. Oxfendazole has four main metabolites fenbendazole, fenbendazole sulphone, p-hydroxy fenbendazole and fenbendazole amine. While oxfendazole and fenbendazole are anthelmintically active, the other metabolites have minimal or no anthelmintic activity.
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Citric Acid monohydrate
Colloidal anhydrous Silica
Not to mix the product with other medicinal products.
6.3 Shelf life
Shelf life of the veterinary medicinal product as packaged for sale: 3 years
6.4 Special precautions for storage
Protect from frost. Protect from direct sunlight.
6.5 Nature and composition of immediate packaging
1 litre, 2.5 litre, 5 litre and 10 litre white high-density polyethylene jerricans with polyethylene (screw-fit) closures.
1 litre, 2.5 litre and 5 litre high-density polyethylene flexipacks with polypropylene (screw-fit) closures.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused product or waste material should be disposed of in accordance with national requirements. Do not contaminate ponds, waterways or ditches with the product or used container.
7. MARKETING AUTHORISATION HOLDER
Chanelle Animal Health Ltd
7 Rodney Street
8. MARKETING AUTHORISATION NUMBER
9. DATE OF FIRST AUTHORISATION
Date:21 March 1994
DATE OF REVISION OF THE TEXT
22 January 2014
Page 7 of 7